CD19 and post-transplant lymphoproliferative disease: It is worthwhile noting that CD19 CAR-T products have been used in the treatment of post-transplant lymphoproliferative disease (PTLD) [12], but no cases of PTLD occurring after autologous CAR-T have been reported so far.